The clinicopathological characteristics, oncologic outcomes and costs of "HER2-low" early breast cancer compared to HER2-zero and HER2-positive: a single-centre retrospective analysis
{{output}}
Background: Breast cancer is a heterogeneous disease commonly classified based on hormone receptor (HR) status and human epidermal growth factor receptor 2 (HER2) expression. Recently, an intermediate category termed "HER2-low"... ...
